All In Biotech

Drug Trial Radar · NCT07680478

Nutrition Intervention Combined With Resmetirom for MASH

Assessing Nutrition-aligned Resmetirom Roll-out

Last checked: Nov 20, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Oct 1, 2026

Primary completion

Feb 28, 2028

Study completion Jun 30, 2028

Sponsor

Lead sponsor
City University of New YorkAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized control trial aims to evaluate the effectiveness of combining resmetirom therapy (first approved pharmacological therapy for treating metabolic dysfunction-associated steatohepatitis (MASH)) with a nutritional intervention compared to resmetirom therapy alone over one year in improving liver health among 120 patients living with non-cirrhotic MASH. We hypothesize that patients receiving resmetirom and nutritional intervention will experience more significant improvements in liver function than those receiving only resmetirom therapy.

Conditions

  • Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Interventions

  • Resmetirom therapyDrug

    All participants involved in the study will receive treatment according to resemetirom protocol: For patients weighing: * \<100 kg, the recommended dosage is 80 mg orally, once daily * ≥100 kg, the recommended dosage is 100 mg orally, once daily

  • Comprehensive nutritional interventionBehavioral

    The nutritional intervention will consist of two components: 1. Medically tailored meals (MTMs): Participants will receive 10 MTMs per week delivered by God's Love We Deliver in New York City. Meals will follow Mediterranean diet principles (40% carbohydrate, 35-45% fat, 15-25% protein), be delivered frozen with preparation and safety instructions, and meal preferences will be collected in advance. Participants will be encouraged to eat two meals per weekday and source any additional food independently. 2. Nutritional and physical activity educational support: Online educational materials will be provided at baseline and follow-up visits, covering healthy eating, Mediterranean-diet principles, and exercise recommendations.

  • Standard dietary supportBehavioral

    Participants will receive standard-of-care lifestyle recommendations, including handouts on healthy diet and physical activity, and the option of a telehealth consultation with a dietitian.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MRI-PDFF changeTime frame: Baseline and 12 months
  2. MRE changeTime frame: Baseline and 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CUNY Graduate School of Public Health and Health Policy

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.